All research and development (R & D) at Millennium Pharmaceuticals is focused on the goal of developing breakthrough treatments that will make a real difference in patients’ lives. We believe that the best way to accomplish this is to develop a deep understanding of disease pathways – the networks of molecular mechanisms that underlie serious diseases. By combining this understanding with knowledge of therapeutically important differences that may exist between patients – differences either in disease pathways or in their responsiveness to particular drugs – we seek to enable “personalized medicine." By this we mean providing the right drugs, directed toward the right molecular targets, to the right patients, at the right time.

The value of our focus on disease pathways is illustrated by the pipeline of potential drugs we have in clinical development, which includes molecules targeted to several key pathways: the ubiquitin-proteasome pathway, leukocyte activation and migration, and kinase-mediated signaling.

To add to our clinical pipeline, we have a large number of discovery-stage and preclinical programs, all driven by a powerful R&D engine that combines world-class biology in important disease pathways with an industry-leading technology platform. Over the last decade, this combination has made Millennium the partner of choice for many major pharmaceutical companies seeking to enhance their R&D productivity.

R&D programs at Millennium are focused in two key therapeutic areas, encompassing a range of important diseases: